Search Results for "Epilepsy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Epilepsy. Results 1 to 7 of 7 total matches.
Intranasal Diazepam (Valtoco) and Midazolam (Nayzilam) for Seizure Clusters
The Medical Letter on Drugs and Therapeutics • Apr 20, 2020 (Issue 1596)
patients with epilepsy
experience seizure clusters, a series of grouped seizures
occurring over a brief ...
The FDA has approved nasal spray formulations of
the benzodiazepines diazepam (Valtoco — Neurelis)
and midazolam (Nayzilam — UCB) for acute treatment
of intermittent episodes of frequent seizure activity
(seizure clusters). Diazepam rectal gel (Diastat, Diastat
AcuDial, and generics) has been used for this indication
for many years.
Cannabis and Cannabinoids
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
from the marijuana plant, is FDA-approved to
treat two types of epilepsy. Nabiximols, a standardized
cannabis ...
Cannabis (marijuana) contains more than 60
pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
are the best known. THC is the main psychoactive
constituent of cannabis. CBD, unlike THC, does not
produce intoxication or euphoria.
Stiripentol (Diacomit) for Dravet Syndrome (online only)
The Medical Letter on Drugs and Therapeutics • Mar 24, 2021 (Issue 1620)
myoclonic epilepsy of
infancy) is a rare form of epileptic encephalopathy
characterized by seizure onset ...
The FDA has approved stiripentol (Diacomit – Biocodex)
for treatment of seizures in patients ≥2 years old with
Dravet syndrome who are also taking clobazam (Onfi).
Stiripentol, which has been available in Europe, Canada,
and Japan for many years, is the second drug to be
approved in the US for this indication; cannabidiol oral
solution (Epidiolex), a purified marijuana product, was
the first.
Fenfluramine (Fintepla) for Dravet Syndrome
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
Lett Drugs
Ther 2021; 63:e1.
3. Cannabidiol (Epidiolex) for epilepsy. Med Lett Drugs Ther 2018;
60 ...
The FDA has approved fenfluramine oral solution
(Fintepla – Zogenix) for treatment of seizures in
patients ≥2 years old with Dravet syndrome. It is the
third drug to be approved for this indication. Stiripentol
(Diacomit) and cannabidiol (Epidiolex), a purified
product derived from marijuana, were approved earlier.
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
with epilepsy.
DRUG INTERACTIONS — Patients should avoid concomitant
use of metoclopramide and antipsychotics ...
The FDA has approved Gimoti (Evoke), a nasal
spray formulation of the dopamine-2 (D2) receptor
antagonist metoclopramide, for relief of symptoms in
adults with acute and recurrent diabetic gastroparesis.
Metoclopramide (Reglan, and generics) has been
available for years in conventional and orally-disintegrating
tablets and in an injectable formulation.
It is the only drug that is FDA-approved for treatment
of diabetic gastroparesis.
Cenobamate (Xcopri) for Focal Seizures
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
and may interact with many
other drugs.
1. Drugs for epilepsy. Med Lett Drugs Ther 2017; 59:121.
2. M Nakamura ...
The FDA has approved cenobamate (Xcopri – SK Life
Science) for oral treatment of partial-onset (focal)
seizures in adults.
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
pregnancy. Med Lett Drugs Ther 2013; 55:45.
33. J Weston et al. Monotherapy treatment of epilepsy ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction